We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00206193
Recruitment Status : Unknown
Verified September 2005 by Atrium Medical Center.
Recruitment status was:  Recruiting
First Posted : September 21, 2005
Last Update Posted : October 30, 2007
Information provided by:
Atrium Medical Center

Brief Summary:
The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.

Condition or disease Intervention/treatment Phase
Abortion, Induced Drug: mifepristone Drug: misoprostol Drug: sulprostone Phase 2

Study Type : Observational
Time Perspective: Prospective

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria:

  • Women with liver/kidney disease
  • Women on long-term use of corticosteroids (> 6 months)
  • Cardiovascular problems
  • Therapy-resistant diabetic women
  • Therapy-resistant asthma/bronchitis
  • Thalassemia
  • Ulcerative colitis
  • Peptic ulcer disease
  • Glaucoma
  • Porphyria
  • Allergic reaction to prostaglandin or mifepristone
  • Women with a prior caesarian section or women with contractions at the start of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00206193

Contact: Suzanne HW Vonken, Dr. 003145-5766666 ext 466825 svonken@gmail.com
Contact: F Roumen, Dr. 003145-5766666 ext 466509

Atrium Medisch Centrum Recruiting
Heerlen, Limburg, Netherlands
Contact: Suzanne HW Vonken, Dr.    045-5766666(6825)      
Principal Investigator: Suzanne HW Vonken, Dr.         
Sponsors and Collaborators
Atrium Medical Center
Study Director: F Roumen, Dr. Atrium Medisch Centrum, Heerlen

ClinicalTrials.gov Identifier: NCT00206193     History of Changes
Other Study ID Numbers: TOP-protocol
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: October 30, 2007
Last Verified: September 2005

Keywords provided by Atrium Medical Center:
termination of pregnancy

Additional relevant MeSH terms:
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents